Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
ClinicalTrials.gov study NCT07193160. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
ClinicalTrials.gov study NCT00421694. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT05045404. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
ClinicalTrials.gov study NCT02691871. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
ClinicalTrials.gov study NCT04882345. IPD Sharing: NO. Countries: 0. Publications: 0.
Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC
ClinicalTrials.gov study NCT05534113. IPD Sharing: NO. Countries: 0. Publications: 0.
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
ClinicalTrials.gov study NCT06890182. IPD Sharing: Not stated. Countries: 0. Publications: 0.
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generatio
ClinicalTrials.gov study NCT05497076. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
ClinicalTrials.gov study NCT05862194. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
ClinicalTrials.gov study NCT05994339. IPD Sharing: NO. Countries: 0. Publications: 0.
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
ClinicalTrials.gov study NCT04874844. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Orlistat Overcoming Third-generation EGFR-TKI Resistance
ClinicalTrials.gov study NCT06818955. IPD Sharing: NO. Countries: 0. Publications: 0.
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC
ClinicalTrials.gov study NCT06436144. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
ClinicalTrials.gov study NCT06323148. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT07256509. IPD Sharing: Not stated. Countries: 0. Publications: 0.
AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC
ClinicalTrials.gov study NCT06508606. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
ClinicalTrials.gov study NCT04284631. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
ClinicalTrials.gov study NCT05934461. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
ClinicalTrials.gov study NCT06418724. IPD Sharing: Not stated. Countries: 0. Publications: 0.
SOX2 epidermal overexpression promotes cutaneous wound healing via activation of EGFR/MEK/ERK signaling mediated by EGFR ligands
GEO Series GSE118859. Mus musculus. 15 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.